BACKGROUND: Disseminated intravascular coagulation (DIC) is noted in severe cases of coronavirus disease 2019 (COVID-19). Recently, a number of studies evaluating the diagnosis and treatment of DIC in COVID-19 patients have been reported .
OBJECTIVE: The aim of this study is to identify existing gaps where further research is needed on the diagnosis and treatment of DIC complicated by COVID-19 .
METHODS: We used the PRISMA Extension for Scoping Reviews . MEDLINE, CENTRAL, WHO-ICTRP, ClinicalTrial.gov and PROSPERO were searched from their inception to 6 October 2020 .
RESULTS: Seven studies were selected; five were already published and two are ongoing . DIC was diagnosed using the International Society on Thrombosis and Hemostasis (ISTH) DIC score (n = 4) and the sepsis-induced coagulopathy (SIC) DIC score (n = 5). Seven studies examined the effectiveness of low molecular weight heparin (LMWH); of these, four studies used a prophylactic dose and five used a therapeutic dose of LMWH . A prophylactic dose of unfractionated heparin (UFH) was investigated in two studies .
CONCLUSION: Studies on DIC diagnostic criteria and anticoagulants were limited to the ISTH or SIC scores and heparinoids, particularly LMWH . Further studies are needed to compare these with other available DIC scoring systems and anticoagulants.
Index: Anticoagulants, COVID-19, Coagulopathy, Disseminated intravascular coagulation, Scoping review